Low-cost linkage? 10 drugs suspended in Shanghai for one year Shutai God, four-ring medicine...

Author . . . Linan September 17, Shanghai Pharmaceutical Centralized Tendering and Procurement Services Management Institute issued a notice, according to the "on further strengthening the city's medical insurance fixed-point medical institutions out-of-the-fund drug procurement and use management notice" (Shanghai People's Social Medicine (2017) No. 263) and "on the further improvement of this From September 22, Shanghai will suspend the purchase qualification of 10 drugs that do not comply with the relevant provisions of the self-expensed drug network for one year, involving nine pharmaceutical enterprises.
10 self-cost drugs have the first batch of national key monitoring drugs: Malay acid cinnamon zitt injection, forefront of the injection, Changchun citin injection, Idarafeng injection, injection mouse nerve growth factors, as well as the third batch of national varieties of metformin hydrochloride slow release tablets, production enterprises involved in Beijing four rings, Shutai God, Qingdao Baiyang and so on.
Searly pictured: suspended from the internet or because of the "price" 2017 Shanghai "on the further improvement of the city's self-financing drug network procurement notice" requirements, pharmaceutical companies should take the initiative to declare the basic information of self-financing drugs and 15 provinces and cities procurement prices and update information, the municipal pharmaceutical companies will regularly in the sun platform inquiry bargaining system to all pharmaceutical manufacturers and medical institutions to disclose the relevant price information, accept social supervision.
five provinces and cities refers to the same varieties of enterprises in Beijing, Tianjin, Jiangsu, Zhejiang, Guangdong five provinces and cities on the provincial drug procurement platform purchase prices.
10 provinces and cities procurement price: refers to the same varieties of enterprises in Chongqing, Anhui, Fujian, Jiangxi, Shandong, Henan, Hebei, Liaoning, Hubei, Hunan, ten provinces and cities on the provincial drug procurement platform purchase price.
If there is an misstal or underst report on the purchase price of 15 provinces and cities, after verification with the state management platform, suspend the qualification of the hanging network involving drugs for 1 year, and if more than 3 times (inclusive) occur cumulatively within 1 year of the same enterprise, suspend the qualification of all self-financing drugs of the enterprise for 1 year.
noteworthy, as recently as September 15, Ningxia Public Resources Trading Service Center also issued a "notice on the publicity of some drugs to adjust the price", some prices higher than the country's lowest five provinces to adjust the price of products.
notice noted that "113 drugs were found to be higher than the winning bid list prices in the five lowest provinces in the country" in price monitoring of the top 200 drugs purchased for the whole year of 2019.
this year, Guangdong, Shaanxi, Yunnan and other provinces have also issued a text for price dynamic adjustment, drug prices are clearly linked to the national trend.
focus on monitoring the collection of drugs, centralized bargaining in order to further prevent clinical abuse, save health insurance funds.
June 30 this year, most provinces had adjusted the state's focus on monitoring drugs, which no longer fall under medicare reimbursements.
, on the other hand, some provinces and cities will focus on monitoring drugs into the collection, or centralized bargaining, to further standardize drug use.
For example, Qinghai Province last year included in the collection of 20 key monitoring drug specifications, such as sodium monosalic acid neural glycoside, cerebroside carnosine, calf serum deprotein, etc.; Er, Idarafeng, sodium crea acid four key monitoring drugs, in August this year, Wuhan City on the city's 30 key monitoring drugs centralized bargaining (including the first batch of 20 national key monitoring drugs), the collection did not give "quantity", but asked enterprises to reduce by 30%.
Wuhan focus on monitoring drug belt procurement, the final 15 kinds of drugs 24 product prices successfully, it is known that with the provincial platform prices than the average decline of 42.7%, the highest decline of 69.59%;
is not difficult to predict, the future of local collection prices will affect the whole country, after the collection of key monitoring drugs significantly reduced prices in inevitable.
According to Sina Pharma previously understood that 20 countries focus on monitoring drugs involved in as many as 200 enterprises, mainly four ring medicine, Fosun Pharma, Lizhu Group, Kun Pharmaceutical Group, Saisheng Pharmaceuticals, Step Pharmaceuticals, Shutai Shen and so on.
Among them, Shanghai suspended the procurement of drugs for one year, injection mouse neurogrowth factor was once the main source of revenue for The God of Shutai, Malay acid cinnamon zitting for the four-ring medicine domestic best-selling cardiovascular disease drugs ... Qingdao Baiyang Naida intends to mainly attack the off-court market? Also suspended in Shanghai is Qingdao Baiyang's slow release of metformin hydrochloride (III.).
the drug had just been purchased in volume.
August 20, the third batch of state mining in Shanghai, the same day bid information shows that metformin slow release control agent type 500mg, Qingdao Yellow Sea quote 9 yuan / 30 pieces, Merck quote 42.04 yuan / 30 Tablets, medicine Xinyi quoted 8.99 yuan / 30 tablets, Qingdao Baiyang quoted 123 yuan / 30 tablets, as the original research manufacturer Merck's price is much higher than in addition to Qingdao Baiyang other domestic generic pharmaceutical companies, Qingdao Baiyang's quotation is also of great concern.
understand that Qingdao Baiyang production of metformin is quoted high, because its dosage form and domestic generic drugs are not the same.
of this year, Qingdao Baiyang's osmotic pump-controlled release agent type metformin slow release tablets (III.) (commodity name: Nida) officially opened in China.
in terms of pricing, the price of the product is about twice the price of ordinary domestic slow-release products, in the United States, the price ratio between the two is as high as 87 times.
In addition to the out-of-hospital market, Qingdao Baiyang itself has a wealth of off-court retail channels, in the third batch of national mining to opt out is not too surprising, but this time by Shanghai suspended procurement for a year, the new dosage form of metformin is good but high prices will undoubtedly lose some of the hospital market.
2020 health insurance catalog adjustment in that, Baiyang side has publicly disclosed that it will actively promote metformin into the health insurance reimbursement directory.
However, in the third batch of harvesting, metformin 0.5g and 0.25g of the two maximum price reduction range of more than 90%, sugar-lowering "god medicine" metformin per tablet as low as 1.5 cents.
the decline in the national health care negotiations, companies need to be good enough to cut prices if they want to get in.
.